Šalis: Didžioji Britanija
kalba: anglų
Šaltinis: MHRA (Medicines & Healthcare Products Regulatory Agency)
Carvedilol
Genus Pharmaceuticals Ltd
C07AG02
Carvedilol
12.5mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02040000
1 PACKAGE LEAFLET: INFORMATION FOR THE USER CARVEDILOL 3.125 MG, 6.25 MG, 12.5 MG & 25 MG TABLETS CARVEDILOL READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINEBECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any of the side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. IN THIS LEAFLET : 1. What CARVEDILOL is and what it is used for 2. What you need to know before you take CARVEDILOL 3. How to take CARVEDILOL 4. Possible side effects 5. How to store CARVEDILOL 6. Contents of the pack and other information 1. WHAT CARVEDILOL IS AND WHAT IT IS USED FOR Carvedilol belongs to a group of medicines called beta-blockers that works by relaxing and widening the blood vessels. This makes it easier for your heart to pump blood around the body and reduces blood pressure and strain on your heart. Carvedilol is used: • for the treatment of high blood pressure (hypertension). • for the treatment of chest pain that occurs when the arteries that supply your heart with blood carrying oxygen are narrowed which results in less oxygen reaching your heart muscles (angina), • for the treatment of weakening of the heart muscle (heart failure), in combination with other medicines. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE CARVEDILOL DO NOT TAKE CARVEDILOL: - if you are allergic to carvedilol or any of the other ingredients of this medicine (listed in section 6) - if you have a history of wheezing due to asthmatic or other lung diseases. - if you have been told you have very severe fluid retention (swelling) which is being treated with injections of medicines into one of your veins (intravenously). - if you have liver disease. - if you have been told th Perskaitykite visą dokumentą
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Carvedilol 12.5 mg Tablets SUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 12.5 mg of Carvedilol Excipient(s) with known effect: Each tablet contains 62.94 mg of lactose For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet Carvedilol Tablets are cream coloured, circular, biconvex tablets, 8.30 mm-8.70 mm in diameter, marked ‘C12’ on one face and plain on the reverse face. SUMMARY OF PRODUCT CHARACTERISTICS 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Essential hypertension Chronic stable angina pectoris Adjunctive treatment of moderate to severe stable chronic heart failure. SUMMARY OF PRODUCT CHARACTERISTICS 4 CLINICAL PARTICULARS 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology ESSENTIAL HYPERTENSION Carvedilol may be used for the treatment of hypertension alone or in combination with other antihypertensives, especially thiazide diuretics. Once daily dosing is recommended, however the recommended maximum single dose is 25 mg and the recommended maximum daily dose is 50 mg. _ _ _Adults:_ The recommended initial dose is 12.5 mg once a day for the first two days. Thereafter the treatment is continued at the dose 25 mg/day. If necessary, the dose may be further increased gradually at intervals of two weeks or more rarely. _Elderly:_ The recommended initial dose in hypertension is 12.5 mg once a day which may also be sufficient for continued treatment. However, if the therapeutic response is inadequate at this dose, the dose may be further increased gradually at intervals of two weeks or more rarely. CHRONIC STABLE ANGINA PECTORIS: A twice-daily regimen is recommended. _Adults:_ The recommended initial dosage is 12.5 mg twice a day for the first two days. Thereafter, the treatment is continued at the dose 25 mg twice a day. If necessary, the dose may be further increased gradually at intervals of two weeks or more rarely to the recommended maximum dose of 100 mg Perskaitykite visą dokumentą